A Phase 3 interventional study of Rcombinant botulinum toxin type A for injection（Eveotox) and OnabotulinumtoxinA (Botox) in Moderate to Severe Glabellar Lines, sponsored by JHM BioPharma (Tonghua) Co. , Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by JHM BioPharma (Tonghua) Co. , Ltd. · Phase 3, Interventional, and Treatment
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
JHM BioPharma (Tonghua) Co. , Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eveotox, 20 Units, divided into five injections into the glabellar area. Administered in double-blind fashion at cycle 1 followed by up to 3 open-label cycles.
Biological: Rcombinant botulinum toxin type A for injection（Eveotox)
Botox,20 Units, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units).
Biological: OnabotulinumtoxinA (Botox)
Placebo, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units)
Biological: Placebo
Rcombinant botulinum toxin type A for injection（Eveotox)
OnabotulinumtoxinA (Botox)
Placebo
Primary Outcome Measure
Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit relative to baseline, based on both the investigators´ and the subjects´ in-clinic assessments.
Time frame: Within 4 weeks
Secondary Outcome Measure
Incidence of serious adverse events and drug-related adverse events during the study.
Time frame: Within 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JHM BioPharma (Tonghua) Co. , Ltd.